Management Team
Resolvyx has brought together a team of dedicated, innovative scientists who bring a broad range of skills and expertise to move forward this ground breaking technology.
Philip J. Vickers, PhD
Chief Scientific Officer, Resolvyx Pharmaceuticals
Dr. Vickers holds a Ph.D. in Biochemistry from the University of Toronto and a Bachelor of Science degree in Applied Biochemistry from the University of Salford, Manchester, England. Before joining Resolvyx, Dr. Vickers was Senior Vice President and Head of US Research for Boehringer-Ingelheim. Prior to Boehringer-Ingelheim, Dr. Vickers served as Vice President for Pfizer Global Research and Development and head of the Pfizer Research Technology Center in Cambridge, MA. He previously held various leadership positions within Pfizer's R&D organization including Executive Director of Genomic and Proteomic Sciences, and he served on the Pfizer Discovery Technology Board and the Pfizer Research Leadership Team. Dr. Vickers had previously worked at Merck Research Laboratories where his group conducted fundamental work on 5-lipoxygenase and cyclooxygenase-2 enzymes, resulting in the development of novel anti-inflammatory compounds.
Per Gjorstrup, MD PhD
Co-founder and Chief Medical Officer
Per Gjorstrup received his MD and PhD in physiology from the University of Lund, Sweden, where he was associate professor of physiology before joining industry. He brings over 25 years of experience in research and development with pharmaceutical and biotechnology companies, most recently as Chief Medical Officer at Micromet, Munich, Germany. Earlier industry positions include Section Leader Pharmacology at Astra (Astra-Zeneca). He later held positions as Head of Immunotherapeutics at Pharmacia, Sweden; senior director for clinical development at Biogen. He has served as advisor to VC groups and start-up companies and has published extensively in leading scientific journals.
James Nichols, PhD
Chief Operating Officer
Head of Corporate Development
Jamie Nichols graduated from Columbia University and earned his Ph.D. in neuroscience from the University of Pennsylvania. He was subsequently a Helen Hay Whitney Postdoctoral Fellow in neurobiology at Stanford University. Prior to joining the Resolvyx team in August, 2007, Dr. Nichols was vice president of therapeutics at CombinatoRx, Inc. In that role, he oversaw multiple R&D programs from discovery through phase II development across a range of therapeutic areas including inflammation, metabolic disease, dermatology, and ophthalmology. Previously, Dr. Nichols was a consultant at Braun Consulting, a healthcare- focused consulting firm (now acquired by Fair Isaac), where he advised senior executives in the biopharmaceutical industry on commercialization and development strategy.
C. Eric Schwartz, PhD
Vice President of Chemistry
Eric Schwartz joined the Resolvyx management team as Senior Director for Medicinal Chemistry in February 2006. He started his medicinal chemistry career at Eisai Research Institute and then held positions as Director of Medicinal Chemistry at UCB Pharma's drug discovery group in Cambridge, MA and as Associate Director in Chemistry at Biogen Idec. He received his Ph.D. in synthetic organic chemistry from the University of Wisconsin - Madison and followed this with a post-doctoral fellowship at the University of Pittsburgh.